What is the likelihood of local anesthetic systemic toxicity (LAST) in a 77.2 Kg patient administered 36cc's of lidocaine (local anesthetic) without epinephrine (adrenergic receptor agonist) over 3 hours?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The risk of local anesthetic systemic toxicity (LAST) in this 77.2 kg patient receiving 36 cc of lidocaine without epinephrine over 3 hours is very low. Assuming standard 1% or 2% lidocaine concentrations, this would equate to 360-720 mg total dose. According to the guidelines for monitoring and management of pediatric patients before, during, and after sedation for diagnostic and therapeutic procedures 1, the maximum recommended dose of plain lidocaine is approximately 4.5 mg/kg, giving this patient a maximum safe dose of about 347 mg. However, the extended administration period of 3 hours significantly reduces toxicity risk, as lidocaine has a relatively short half-life (1.5-2 hours) allowing for metabolism and clearance during the procedure.

Key Considerations

  • The absence of epinephrine means there's no vasoconstriction to slow absorption, but the gradual administration compensates for this.
  • Clinicians should still monitor for early LAST symptoms including perioral numbness, metallic taste, lightheadedness, tinnitus, and visual disturbances, progressing to more serious cardiovascular and central nervous system effects if toxicity develops.
  • Factors that could increase risk include liver dysfunction, heart failure, acidosis, or concurrent medications that might compete for metabolism pathways.

Recommendations for Safe Administration

  • Use the lowest effective dose of local anesthetic, as recommended by guidelines for the use of local anesthesia in office-based dermatologic surgery 1.
  • Aspirate the needle/catheter prior to each injection to avoid introducing the drug directly into a vessel.
  • Use incremental injections of anesthetic and continually assess and communicate with the patient to monitor for signs of early toxicity.

From the FDA Drug Label

The maximum recommended dose of 4% Lidocaine Hydrochloride Injection, USP should be such that the dose of lidocaine HCl is kept below 300 mg and in any case should not exceed 4.5 mg/kg (2 mg/lb) body weight. When used without epinephrine, the amount of lidocaine administered should be such that the dose is kept below 300 mg and in any case should not exceed 4.5 mg/kg (2 mg/lb) of body weight.

The patient weighs 77.2 Kg and was administered 36cc's of lidocaine. Assuming a 4% lidocaine solution (40mg/mL), the total dose administered is 36cc * 40mg/mL = 1440mg.

This dose exceeds the maximum recommended dose of 300mg and 4.5mg/kg (4.5mg/kg * 77.2Kg = 347.4mg).

Therefore, the likelihood of local anesthetic systemic toxicity (LAST) is high 2.

From the Research

Local Anesthetic Systemic Toxicity (LAST) Risk Assessment

The administration of 36cc's of lidocaine without epinephrine over 3 hours to a 77.2 Kg patient poses a risk of local anesthetic systemic toxicity (LAST). The likelihood of LAST can be assessed based on several factors, including:

  • The dose and volume of lidocaine administered
  • The site of injection
  • The patient's weight and comorbidities
  • The presence of susceptible factors, such as advanced heart failure 3

Factors Influencing LAST Risk

Several studies have identified factors that influence the risk of LAST, including:

  • Local anesthetic type, dosage, and volume 4
  • Site of injection 4
  • Patient comorbidities, such as advanced heart failure 3
  • The use of epinephrine, which can help reduce the risk of LAST by slowing the absorption of lidocaine 5

Clinical Presentation of LAST

The clinical presentation of LAST can vary, but common symptoms include:

  • Seizures 6, 4
  • Cardiac arrhythmias 7
  • Refractory cardiac dysfunction 7
  • Dysrhythmias 7
  • Prearrest situations 7

Prevention and Management of LAST

Prevention and management of LAST are critical to reducing the risk of morbidity and mortality. Strategies for prevention and management include:

  • Using the minimum effective dose of lidocaine 4
  • Monitoring patients closely for signs of LAST 4
  • Having a plan in place for emergency treatment, including lipid emulsion therapy 5, 4
  • Educating physicians on the recognition and management of LAST 4

Related Questions

What is the risk of local anesthetic systemic toxicity (LAST) in a 72.72 Kg adult patient who received 3cc's of 1% lidocaine (lidocaine) with epinephrine (epinephrine) + 6cc's of 2% lidocaine (lidocaine) without epinephrine (epinephrine) in the first hour, followed by 24cc's of 2% lidocaine (lidocaine) without epinephrine (epinephrine) over the next 2 hours?
What is the likelihood of developing lidocaine (local anesthetic) toxicity in a 72.72 kg patient who received 3cc's of 1% lidocaine (local anesthetic) without epinephrine (adrenergic receptor agonist) and 30cc's of 2% lidocaine (local anesthetic) without epinephrine (adrenergic receptor agonist) over 3 hours for local anesthesia?
What is the management of ECG (Electrocardiogram) changes in Local Anesthetic Systemic Toxicity (LAST)?
What is the significance of an accidental intramuscular (IM) injection of 2 milliliters (mL) of lidocaine (0.1% solution)?
What are the complications of total spinal anesthesia causing central nervous system symptoms?
What are the possible causes and treatments for mildly enlarged hypermetabolic mediastinal and hilar lymph nodes up to 1.2 cm in size, and how can reactive versus other causes be differentiated?
What is the workup for a patient with poorly controlled Hypertension (HTN)?
What is the recommended management for a 38-year-old female with severe left knee pain and instability after falls related to syncope, with MRI findings of insertional quadriceps tendinopathy, iliotibial band friction syndrome, and shallow chondral lesions?
What's the next step for a patient with elevated Hemoglobin A1c (HbA1c) on maximum doses of metformin (Metformin) and Victoza (Liraglutide), and 7 units (U) of Humalog (Insulin Lispro) three times a day (TID)?
What is the diagnosis and treatment for a patient with a partially ruptured Baker's cyst, mild meniscal and ligamentous issues, and chondral heterogeneity in the left knee?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.